Cardio ThinkLab
 

ESC 2021 Heart Failure Guidelines: What’s new?

Heart Failure Classification

What has changed?
  • Natriuretic peptides are one of the criteria in the definition of HF.
  • The nomenclature for HF with LVEF of 41-49% has been revised to HF with mildly reduced ejection fraction or HFmrEF.
LVEF ≥50%

HF signs and symptoms. Evidence of structural and/or functional cardiac abnormalities and/or raised NPs

LVEF – 41% – 49%

Mildly reduced
LV ejection fraction

LVEF ≤40%

Significant reduction
in LV ejection fraction

Updated Criteria for the Definition of Advanced Heart Failure

All of the following criteria must be present despite optimal medical treatment:

Patient placing one hand on chest experiencing symptoms of heart failure. Severe and persistent symptoms of heart failure [NYHA class III (advanced) or IV]. ""
Severe cardiac dysfunction defined by at least one of the following:
  • LVEF ≤30%
  • Isolated RV failure (e.g., Arrhythmogenic right ventricular cardiomyopathy)
  • Non-operable severe valve abnormalities
  • Non-operable severe congenital abnormalities
  • Persistently high (or increasing) BNP or NT-proBNP values and severe LV diastolic dysfunction or structural abnormalities (according to the definitions of HFpEF)
What has changed?

Natriuretic peptides (NP) are part of the definition of advanced heart failure.

"" Episodes of pulmonary or systemic congestion requiring high-dose i.v. diuretics or episodes of low output requiring inotropes or vasoactive drugs or malignant arrhythmias causing >1 unplanned visit or hospitalization in the last 12 months. Person looking down and feeling fatigued from exercise. Severe impairment of exercise capacity with inability to exercise or low 6MWT distance (<300 m) or pVO2 <12 mL/kg/min or <50% predicted value, estimated to be of cardiac origin.
Chronic Heart Failure –

Patient Care Pathway

Patient placing one hand on chest experiencing symptoms of heart failure.

PATIENT WITH SUSPECTED HF

  • Shows typical signs and symptoms – breathlessness, fatigue, and ankle swelling
  • Presence of risk factors
  • Abnormal ECG
Lab technician's hand holding test tube for Initial diagnostic test for heart failure.

INITIAL DIAGNOSTIC TESTS

BNP <35 pg/mL Or NT-proBNP <125 pg/mL Or MR-proANP <40 pmol/L
  • HF unlikely
  • Consider other diagnoses
NT-proBNP ≥ 125 pg/mL Or
BNP ≥ 35 pg/mL
  • May be HF
  • Proceed to echocardiography
Echocardiography conducted if heart failure is suspected.

ECHOCARDIOGRAPHY

If normal echocardiography
  • HF unlikely
  • Consider other diagnoses
If abnormal echocardiography
  • HF is confirmed
  • Define HF phenotype
LVEF
≤40%HFrEF
41-49%HFmrEF
≥50%HFpEF
Icon of pill bottle and a pill.

TREATMENT

HFrEF
HFmrEF
HFpEF
Guideline Recommended Pharmacological Treatment Suspected HF patient looking at computer and receiving an online diagnosis from a doctor.

FOLLOW-UP CARE

  • General follow-up every 6 months.
  • Current evidence does not support the routine measurement
    of BNP or NT-proBNP to guide titration of therapy.
Acute Heart Failure –

Patient Care Pathway

Patient holding both hands on chest and suffering from acute HF symptoms.

PATIENT WITH SUSPECTED ACUTE HF

  • Clinical history
  • Signs and/or symptoms suspected of acute HF
Icons of diagnostic tests for Heart Failure such as Electrocardiography, Pulse oximetry and Chest X-ray

DIAGNOSTIC TESTS

  • Electrocardiogram
  • Pulse oximetry
  • Echocardiography
  • Initial laboratory investigations including troponin
  • Chest x-ray
  • Lung ultrasound
  • Coronary angiography, if suspected ACS
  • CT, if suspected pulmonary embolism
Lab technician's hand holding a test tube.

NATRIURETIC PEPTIDES MEASUREMENT

Normal levels of NPs
  • BNP <100 pg/mL
  • NT-proBNP <300 pg/mL
  • MR-proANP <120 pg/mL
  • Rule out AHF
Elevated NPs
  • BNP ≥100 pg/mL
  • NT-proBNP ≥300 pg/mL
  • MR-proANP ≥120 pg/mL
  • AHF confirmed
Icon of an ambulance with siren on.

PRE-HOSPITAL PHASE

  • Non-invasive monitoring – Started within minutes
    of patient contact and in the ambulance if possible
  • Oxygen therapy
  • Non-invasive ventilation, if respiratory distress
Icon of a hospital.

IN-HOSPITAL MANAGEMENT

Cardiogenic shock and/or respiratory failure YES
  • Pharmacological support
  • Ventilator support
  • Mechanical circulatory support
NO

Identify acute aetiology

YES

Start specific treatment immediately

NO

Further treatment differs according to the clinical presentations

<!– << "" <!– <<

PRE-DISCHARGE ASSESSMENT

  • Optimize treatment to keep the patient free of congestion
  • Continue oral optimal medical therapy in ADHF (reduce dose or withdraw if haemodynamic instability, severely impaired renal function or hyperkalaemia)
<!– << HF patient standing in front of a hospital. <!– <<

POST-DISCHARGE MANAGEMENT

  • One follow-up visit within 1 to 2 weeks after discharge
  • Monitoring of signs and symptoms of HF
  • Assessment of volume status, BP, heart rate
  • Laboratory tests – renal function, electrolytes, and NPs
  • Assessment of iron status and hepatic function
  • Consider further optimization and/or initiation of disease-modifying treatment for HFrEF
Reference

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14;:]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27(1):47-72.

Abbreviations

6MWT: 6-minute walk test; ACS: Acute coronary syndrome; ADHF: Acutely decompensated heart failure; AHF: Acute heart failure; ARVC: Arrhythmogenic right ventricular cardiomyopathy; BNP: B-type natriuretic peptide; CT: Computed tomography; ECG: Electrocardiogram; HF: Heart failure; HFmrEF; Heart failure with mildly reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; HFrEF: Heart failure with reduced ejection fraction; i.v.: Intravenous; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MR-proANP: Mid-regional pro-atrial natriuretic peptide; NPs: Natriuretic peptides; NT-proBNP: N-terminal pro-B-type natriuretic peptide; NYHA: New York Heart Association; pVO2: Peak exercise oxygen consumption; RV: Right ventricular/ventricle.

""
const popBtn = ‘.popup-btn’; const popMdl = ‘.popup-mdl’; const popupBtns = document.querySelectorAll(popBtn); let indexed = -1; popupBtns.forEach((btn, index) => { btn.addEventListener(‘click’, () => { if (index !== indexed) { if (popupBtns[indexed]) removeActive(popupBtns[indexed]); haveActive(popupBtns[index]) ? removeActive(popupBtns[index]) : setActive(popupBtns[index]); indexed = index; } else { removeActive(popupBtns[index]); indexed = -1; } }); }); window.addEventListener(‘click’, (e) => { if (indexed > -1 && !isIt(e, popBtn) && !isIt(e, popMdl)) { removeActive(popupBtns[indexed]); indexed = -1; } }); function haveActive(ele) { return ele.classList.contains(‘active’); } function setActive(ele) { ele.classList.add(‘active’); } function removeActive(ele) { ele.classList.remove(‘active’); } function isIt(e, cls) { return e.target.closest(cls); } ///////////////////////////////////////////////////////////////////////////////////////////////////// // document.documentElement.ondblclick = function () { // this.classList.toggle(‘alt’); // }

President of APSC Cofound of digital trends in Asia

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy.

28 March 2023
Prof Alexandre Mebazaa

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi